Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Licensing revenue and deferred revenue (Details)

v3.19.1
Licensing revenue and deferred revenue (Details)
$ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
USD ($)
Dec. 31, 2018
CAD ($)
Dec. 31, 2017
USD ($)
Aug. 23, 2010
USD ($)
Disclosure of joint ventures [line items]        
Licensing revenue $ 118   $ 418  
Current portion of deferred revenue (note 9) 118   118  
Deferred revenue (note 9) 324   442  
Contravir Pharmaceuticals, Inc. [Member]        
Disclosure of joint ventures [line items]        
Revenue from contracts with customers 345 $ 450    
MAH [Member]        
Disclosure of joint ventures [line items]        
Licensing revenue     300  
MAH [Member] | VOS [Member]        
Disclosure of joint ventures [line items]        
Licensing revenue     300  
3SBio [Member]        
Disclosure of joint ventures [line items]        
Licensing revenue 118   118  
Licence fee income       $ 1,500
Deferred revenue (note 9) $ 442   $ 560